Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation by Drug Type
6.1 Antibiotic Derivatives
6.2 Ionophore Derivatives
6.3 Amprolium Derivatives
6.4 Sulphonamides Derivatives
6.4 Ethopabate Derivatives
6.5 Clopidol Derivatives
6.6 Quinolones Derivatives
6.7 Other Derivatives
Chapter 7Market Segmentation by Animal Type
7.1 Poultry
7.2 Swine
7.3 Fish
7.4 Cattle
7.5 Companion Animals
7.5.1 Dogs
7.5.2 Cats
7.5.3 Ruminants
7.6 Others
Chapter 8 Market Segmentation by Geography
8.1 Asia Pacific
8.1.1 Introduction
8.1.2 China
8.1.3 India
8.1.4 Japan
8.1.5 Australia
8.1.6 Others
8.2 North America
8.2.1 Introduction
8.2.2 United States
8.2.3 Canada
8.2.4 Mexico
8.2.5 Others
8.3 Europe
8.3.1 Introduction
8.3.2 Spain
8.3.3 UK
8.3.4 France
8.3.5 Russia
8.3.6 Italy
8.3.7 Others
8.4 the Middle East and Africa
8.4.1 Introduction
8.4.2 South Africa
8.4.3 Middle East Countries
8.4.4 Others
8.5 South America
8.5.1 Introduction
8.5.2 Argentina
8.5.3 Brazil
8.5.5 Others
Chapter 9 Competitive Landscape
9.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
9.2 Market Share Analysis
9.3 Strategies Adopted By Top Companies
Chapter 10 Company Profiles
10.1 Zoetis
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Strategic Initiative
11.2 Elanco (A Division of Eli Lilly and Company)
11.3 Merial
11.4 Bayer Healthcare Animal Healthcare Division
11.5 Merck Animal Healthcare
11.6 Boehringer Ingelheim Animal Health
11.7 Huvepharma
11.8Virbac
11.9Ceva Santé Animal Healthcare
11.10 Novartis Animal Healthcare
11.11Smartvec Inc.
11.12 Intas
11.13 Dosch Pharmaceuticals
11.14 Jurox
11.15 Biopredic
Chapter 11 Market Estimates and Forecast
11.1 Market Estimates and Forecast 2018-2024(USD Million)
11.1.1 Market Estimation and Forecast by Drug Type 2018-2024(USD Million)
11.1.2 Market Estimates and Forecast by Animal Type 2018-2024(USD Million)
11.1.3 Market Estimates and Forecast by Geography 2018-2024(USD Million)
11.1.4 Market Estimates and Forecast by Company 2018-2024(USD Million)
Chapter 12 Market Insights
12.1 Insights of Industry Experts
12.2 Analyst Opinion (Market Understanding)
12.3 Investment Opportunities
Chapter 13 Appendix
13.1 List of Tables
13.2 List of Figures
